Cardiac Surgery in Patients with Drug Eluting Stents: The Risk of Stopping Clopidogrel
Clinical medicine. Cardiology · 2007
DOI: 10.4137/cmc.s340 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical medicine. Cardiology, 2007. Verfasst von Gorav Ailawadi und 3 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Recommendations for the duration of clopidogrel (Plavix ® , Bristol Meyers Squibb, New York, NY) therapy following drug eluting stent (DES) insertion have been subject to recent criticism. Suggested recommendations for the continuation of clopidogrel have been extended to one year following DES insertion. However, patients with a previously inserted DES who now require cardiac surgery are requested to stop clopidogrel perioperatively. The safety of this practice is unclear. We report two cases of elective cardiac surgical intervention after the insertion of DES complicated by perioperative or intraoperative acute coronary ischemia attributed to DES closure.
Zitieren
APA
Ailawadi, G., Kern, J. A., Peeler, B. B., & Kron, I. L. (2007). Cardiac Surgery in Patients with Drug Eluting Stents: The Risk of Stopping Clopidogrel. Clinical medicine. Cardiology. https://doi.org/10.4137/cmc.s340
Vancouver
Ailawadi G, Kern JA, Peeler BB, Kron IL. Cardiac Surgery in Patients with Drug Eluting Stents: The Risk of Stopping Clopidogrel. Clinical medicine. Cardiology. 2007. doi:10.4137/cmc.s340
BibTeX
@article{Ailawadi2007,
author = {Ailawadi, Gorav and Kern, John A. and Peeler, Benjamin B. and Kron, Irving L.},
title = {Cardiac Surgery in Patients with Drug Eluting Stents: The Risk of Stopping Clopidogrel},
journal = {Clinical medicine. Cardiology},
year = {2007},
doi = {10.4137/cmc.s340}
}
EUVIMED